Vol.

No.

June 07, 2024Jun 07, 2024

DOWNLOAD THE PDF

Cover Story

Most cancer centers provide paltry resources for meeting NCI’s CCSG mandate to enhance diversity, study shows

By Matthew Bin Han Ong

Directors of NCI-designated cancer centers are facing a new set of challenges in a polarizing, high-stakes election year.

Conversation with The Cancer Letter

Fred Hutch’s Christopher Li: Cancer centers should commit more resources to meet NCI’s Plan to Enhance Diversity requirements

By Matthew Bin Han Ong

Clinical

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

By Jacquelyn Cobb and McKenzie Prillaman

Conversation with The Cancer Letter Free

ACS, ASCO combine online patient information services

By Paul Goldberg

Clinical Trials & Tribulations

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

By Rebecca Sutphen

Free In the Archives

Don Dizon and NFN Scout on LGBTQ+ patients with cancer

In Brief

Dennis Slamon receives Szent-Györgyi Prize from National Foundation for Cancer Research

Susan Bullman, Xi Chen named associate members of MD Anderson’s Allison Institute

Harpreet Singh departs FDA, joins Precision for Medicine as chief medical officer

Nominate an emerging leader in IO for SITC’s Steven A. Rosenberg Scholars Award

Clinical Roundup

Black patients who receive docetaxel for breast cancer experience less peripheral neuropathy than those who receive paclitaxel

Sarclisa combination improves PFS in newly diagnosed transplant-ineligible MM in phase III trial

Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

Opdivo + Yervoy improves OS for advanced hepatocellular carcinoma in phase III trial

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

Obe-cel yields strong remission rates in adults with relapsed or refractory B-ALL in phase Ib/II study

Shorter durations of venetoclax yields similar response rates in AML

Antibody-drug conjugate targeting CEACAM5 shows activity in advanced CRC in phase I study preliminary data

USP1 inhibitor combination shows manageable safety profile, anti-tumor activity in metastatic solid tumors in phase I study preliminary data

CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data

Studies detail molecular pathway that impacts pancreatic cancer progression and response to treatment

Drugs & Targets

FDA approves imetelstat for low- to intermediate-1 risk MDS with transfusion-dependent anemia

NCI Trials

NCI Trials for June 2024

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 41 - November 07, 2025